

| PATIENT INFORMATION (Complete or fax existing chart)                             | PRESCRIBER INFORMATION             |
|--|------------------------------------|
| Patient Name: _____  | Prescriber Name: _____             |
| Address: _____   | State License: _____ NPI #: _____  |
| City, State, Zip: _____  | DEA: _____ Phone: _____            |
| Phone: _____ 2 <sup>nd</sup> Phone: _____  | Specialty: _____ Fax: _____        |
| DOB: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female | Address: _____                     |
| Weight: _____ Ht: _____  | City, State, Zip: _____            |
| Allergies: _____   | Contact Person: _____ Phone: _____ |

| INSURANCE INFORMATION - OR - Send a copy of the patient's prescription / insurance cards (front & back) |                             |
|---|-----------------------------|
| Primary Insurance: _____  | RX Card (PBM): _____        |
| City, State, Zip: _____   | BIN: _____ PCN: _____       |
| Plan #: _____ Group #: _____  | City, State, Zip: _____     |
| Phone: _____  | Group #: _____ Phone: _____ |

| DIAGNOSIS / CLINICAL INFORMATION |                       |
|----------------------------------|-----------------------|
| Diagnosis: _____                 | ICD-10 Code(s): _____ |

| KRYSTEXXA® INFUSION ORDERS           |   |
|--------------------------------------|---|
| <b>Dose / Schedule</b>               | 8 mg given as an intravenous infusion every 2 weeks Refills: _____ (If no refills are specified rx is valid for 1 year.)  |
| <b>Labs prior to first treatment</b> | <input type="checkbox"/> Glucose-6-phosphate dehydrogenase (G6PD) deficiency.   |
| <b>Labs prior to each treatment</b>  | <input type="checkbox"/> sUA ~ <b>NOTIFY</b> physician if 2 consecutive serum uric acid levels are over 6 mg/dL - sUA test, preferably within 48 hours of the infusion. |
| <b>Treatment</b>                     | Minimum 2-hours infusion via gravity feed, syringe-type pump, infusion pump and 1-hour post infusion observation time   |
| <b>NaCl</b>                          | 250 mL Krystexxa can be infused in normal saline (0.9% NS) or half-normal saline (0.45% NS)   |

**\*\* DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS. USE ASEPTIC TECHNIQUE. \*\***

| PREMEDICATIONS        |  |   |  |
|-----------------------|--|---|--|
| CLASS                 | DRUG(S)  | DOSING                                    | TIMING IN RELATION TO INFUSION   |
| IV corticosteroids *† | <input type="checkbox"/> 80 mg methylprednisolone<br><input type="checkbox"/> 200 mg hydrocortisone<br><input type="checkbox"/> Other: _____ | Or dose determined by healthcare provider | Prior to each infusion   |
| Antihistamines *†     | <input type="checkbox"/> 60 mg fexofenadine<br><input type="checkbox"/> 50 mg diphenhydramine<br><input type="checkbox"/> Other: _____       | Or dose determined by healthcare provider | Night before infusion, and/or can administer concomitantly with infusion |
| Oral analgesic *†     | <input type="checkbox"/> 1000 mg acetaminophen   | Or dose determined by healthcare provider | Prior to each infusion   |

**\*\*In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate, at the discretion of the physician\*\***

| GOUT FLARE PROPHYLAXIS |                          |   |   |
|------------------------|--------------------------|---|---|
| CLASS                  | DRUG(S)                  | DOSING  | TIMING IN RELATION TO INFUSION  |
| Anti-gout flare agent  | Colcrys® (colchicine)    | Dose determined by healthcare provider<br><br>Patient may take any one of these drugs, as indicated | Daily, treatment initiated 1 week prior to initiation of Krystexxa and lasting at least 6 months, unless medically contraindicated or not tolerated |
| Oral NSAIDs            | Advil®, Aleve®           |   |   |
| Corticosteroids        | Prednisone, prednisolone |   |   |

\* To be given to the patient by nurse on the day of infusion.  
 † Infusion reaction may occur despite pretreatment.

**Inform patients of the symptoms and signs of anaphylaxis and instruct them to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.**

| SIGNATURE           |                       |
|---------------------|-----------------------|
| x _____ Date: _____ | Physician's Signature |

**Important Information:** This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

**Fax completed form to: (800) 783-9146 - Thank you for using BioTek reMEDys®**